Wednesday, July 14, 2021 9:49:53 AM
"Nasdaq is requiring the Company to trade above $4.00 for 10 trading days before we can uplist.”
This is a true statement. But it is SO misleading to shareholders.
I spent two hours going over the Nasdaq requirements in specificity.
There is no way this company qualifies for the Nasdaq. PharmaCyte does not meet the requirements.
Just trading over $4.00 for ten days is one requirement. The company has had 0 revenue for a long time.
Their assets are small.
The Nasdaq requires strong management and sound reputation. I will certainly come back and eat crow if I am wrong but the way I understand it , No way does PMCB qualify for the Nasdaq and it's not even close.
I believe management is getting bolder in misleading shareholders when they say we are going to be listed on the Nasdaq.
This is all just one educated persons opinion.
This is a true statement. But it is SO misleading to shareholders.
I spent two hours going over the Nasdaq requirements in specificity.
There is no way this company qualifies for the Nasdaq. PharmaCyte does not meet the requirements.
Just trading over $4.00 for ten days is one requirement. The company has had 0 revenue for a long time.
Their assets are small.
The Nasdaq requires strong management and sound reputation. I will certainly come back and eat crow if I am wrong but the way I understand it , No way does PMCB qualify for the Nasdaq and it's not even close.
I believe management is getting bolder in misleading shareholders when they say we are going to be listed on the Nasdaq.
This is all just one educated persons opinion.
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM
